Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00149617
Other study ID # NIDA-15440-1
Secondary ID K23DA015440K23-1
Status Completed
Phase Phase 2
First received September 6, 2005
Last updated October 8, 2015
Start date April 2004
Est. completion date December 2007

Study information

Verified date December 2007
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

This study will assess the effectiveness of a combination of buspirone and motivational interviewing therapy in the treatment of marijuana dependence.


Description:

Marijuana dependence is one of the most common substance-related disorders in the United States. Despite its prevalence, there is a lack of clinical research addressing treatments for marijuana dependence. Research has shown that marijuana abuse is associated with affective disorders. This may be caused by repeated use for relief from anxiety. The use of an anxiolytic agent, a drug that relieves anxiety, may help treat marijuana dependence. Motivational enhancement therapy has been shown to reduce marijuana use. Therefore, it is likely that buspirone, which is an anxiolytic agent, combined with motivational enhancement therapy will prove beneficial in treating marijuana dependence. This study will assess the effectiveness of a combination of buspirone and motivational interviewing in the treatment of marijuana dependence.

This double-blind study will last a total of 16 weeks. Participants will be randomly assigned to receive either buspirone or placebo for a period of 12 weeks. There will be one follow-up appointment 4 weeks post-intervention. Baseline assessments will include a physical exam and urine and blood tests. Study visits will occur weekly throughout treatment in order to monitor compliance, assess adverse affects, and obtain substance use data. Mood assessment scales, marijuana craving questionnaires, and a withdrawal symptom checklist will be used to gather the data. Urine drug screens will be collected weekly to test for marijuana use. In addition to this, the presence of opioids, cocaine, amphetamines, and benzodiazepines will be tested at baseline, Weeks 6 and 12, and at follow-up. A 10-day supply of medication will be dispensed to participants each week. Meetings for motivational enhancement therapy will last 30 to 90 minutes each and will occur at baseline, Week 2, and Week 4. Participants' perceived quality of life will be measured at baseline and Weeks 6 and 12 to determine the effect of buspirone.


Recruitment information / eligibility

Status Completed
Enrollment 81
Est. completion date December 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Meets DSM-IV criteria for marijuana dependence

- Lives within 60 miles of the study site

- Willing to provide collateral individuals for contact purposes

- Willing to use an effective form of contraception throughout the study

Exclusion Criteria:

- Meets DSM-IV criteria for dependence upon a substance other than marijuana, nicotine, or caffeine

- Meets DSM-IV criteria for a history of schizophrenia or another non-affective psychotic disorder or bipolar disorder

- Meets DSM-IV criteria for current major depressive disorder or eating disorder

- Significant cognitive impairment

- Currently taking benzodiazepines, antidepressant, or antipsychotic medications

- Major medical illnesses (e.g., HIV, kidney failure, unstable angina, chronic obstructive pulmonary disease, infectious hepatitis)

- Not in stable housing

- Pregnant or breastfeeding

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Buspirone


Locations

Country Name City State
United States Medical University of South Carolina Charleston South Carolina

Sponsors (2)

Lead Sponsor Collaborator
Medical University of South Carolina National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Drug use; measured at Weeks 12 and 16
Secondary Anxiety; measured at Week 12
Secondary Craving; measured at Week 12
Secondary Withdrawal symptoms; measured at Week 12
See also
  Status Clinical Trial Phase
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Recruiting NCT05345392 - Brain, Emotions, and Mind-Wandering N/A
Completed NCT05078450 - Mood Lifters Online for Graduate Students and Young Professionals N/A
Not yet recruiting NCT04551027 - Assessing the Effect of Compensatory Cognitive Intervention Among People With Severe Mental Illness N/A
Recruiting NCT03088657 - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
Active, not recruiting NCT02542475 - Low Field Magnetic Stimulation: Open Label Study. Phase 1/Phase 2
Completed NCT00916552 - Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder Phase 2
Completed NCT00202514 - Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms Phase 2/Phase 3
Completed NCT00217932 - Effectiveness of Divalproex Sodium (Depakote) in Treating Children With Temper Outbursts and Severe Mood Swings Phase 2
Completed NCT00006517 - Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD) N/A
Terminated NCT03898843 - Assisted Animal Therapy: ReAnimal N/A
Active, not recruiting NCT04358900 - Unobtrusive Monitoring of Affective Symptoms and Cognition Using Keyboard Dynamics (UnMASCK)
Recruiting NCT06360562 - Reconnecting to Ourselves and Others in Virtual Meetings (ROOM) N/A
Completed NCT05745103 - Optimizing Behavioral Healthcare Delivery Through Technology N/A
Suspended NCT03715400 - Mobile Virtual Positive Experiences for Anhedonia N/A
Enrolling by invitation NCT03736538 - Nitrous Oxide- Suicidal Ideation Phase 1
Completed NCT04601545 - The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method N/A
Completed NCT02566980 - Biological Triggers of Depression in Pregnancy
Completed NCT03743844 - Psychosocial Intervention for Women With Mood Disorders Seeking Treatment for Obesity N/A
Completed NCT05211063 - Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders N/A